End‐Of‐Life Outcomes and Healthcare Utilization for Patients With Hepatocellular Carcinoma Who Received Immune Checkpoint Inhibition

ABSTRACT Introduction Immune checkpoint inhibitors (ICI) have revolutionized treatment for advanced hepatocellular carcinoma (HCC). However, end‐of‐life (EOL) outcomes and healthcare utilization patterns prior to death for patients who receive ICI compared to non‐ICI as their last therapy are unknow...

Descripció completa

Dades bibliogràfiques

Autors principals:	Margaret C. Wheless, Anna‐Carson R. Uhelski, Sarah K. Cimino, Henry J. Domenico, Sara F. Martin, Mohana B. Karlekar, Thatcher R. Heumann, Kristen K. Ciombor, Laura W. Goff, Rajiv Agarwal
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2025-10-01
Col·lecció:	Cancer Medicine
Matèries:	end‐of‐life goals of care hepatocellular carcinoma immune checkpoint inhibitors
Accés en línia:	https://doi.org/10.1002/cam4.71293
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!